首頁 > 市場調查報告書 > 製藥

個人化醫學

市場調查報告書

商品編碼

1922399

日本伴隨診斷市場報告：按產品/服務、技術、適應症、最終用戶和地區分類（2026-2034年）

Japan Companion Diagnostics Market Report by Product & Service, Technology (Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing, and Others), Indication, End User, and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 117 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2025年，日本伴隨診斷市場規模達5.16億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到13.344億美元，2026年至2034年的複合年成長率為11.48%。癌症發生率上升、對個人化醫療的需求不斷成長以及次世代定序（NGS）等技術進步是推動市場成長的主要因素。

伴隨診斷是一種醫學檢測，旨在幫助醫生確定最佳治療方案。它透過檢測患者組織或血液樣本中存在的特定生物標記物，來預測患者對特定藥物或治療方法的療效。此外，伴隨診斷還能對患者複雜的生物學特徵和作用機制（MOA）進行詳細分析，幫助醫療專業人員了解潛在的藥物副作用。伴隨診斷的廣泛應用在個人化醫療中體現得淋漓盡致。個人化醫療會考慮每位患者的獨特特徵，例如基因組成，以確定最佳治療方案。此外，伴隨診斷也被用於檢測癌症患者的特定基因突變，以及識別丙型肝炎患者的生物標記。

日本伴隨診斷市場的發展趨勢：

日本伴隨診斷市場正經歷顯著成長，主要驅動力是各類癌症發生率的不斷攀升。這推動了對更精準、更具標靶性的癌症治療的需求。此外，針對每位患者個別特徵量身定做的個人化醫療需求日益成長，也進一步支持了市場的良好前景。同時，標靶治療藥物和療法在各種感染疾病、心血管疾病、神經系統疾病和發炎性疾病的廣泛應用，也是市場成長的關鍵促進因素。日本的伴隨診斷監管環境良好，促使核准的檢測項目數量不斷增加。此外，全球臨床試驗的擴展也推動了市場成長。次世代定序（NGS）和液態生物檢體等診斷技術的進步至關重要，使得以往難以檢測的生物標記得以識別。創新基因組技術的發展有助於識別對治療決策至關重要的基因突變和生物標記，從而在推動市場成長方面發揮關鍵作用。此外，在預測期內，生物標記在藥物開發中的應用日益廣泛、對精準醫療的大量投資以及消費者對伴隨診斷益處的認知不斷提高等因素，預計將為區域市場提供有利的成長機會。

本報告解答的關鍵問題

日本伴隨診斷市場目前發展狀況如何？您認為未來幾年它將如何發展？
新冠疫情對日本伴隨診斷市場產生了哪些影響？
日本伴隨診斷市場依產品/服務分類的組成是怎樣的？
日本伴隨診斷市場依技術分類的組成是怎樣的？
日本伴隨診斷市場依適應症分類的詳細情形如何？
日本伴隨診斷市場依最終用戶分類的組成是怎樣的？
請介紹日本伴隨診斷市場價值鏈的各個環節。
日本伴隨診斷的關鍵促進因素和挑戰是什麼？
日本伴隨診斷市場的結構是怎麼樣的？主要參與者有哪些？
日本伴隨診斷市場的競爭程度如何？

Japan companion diagnostics market size reached USD 501.6 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,334.4 Million by 2034, exhibiting a growth rate (CAGR) of 11.48% during 2026-2034. The rising incidence of cancer, the growing need for personalized medicine, and continuous technological advancements like next-generation sequencing (NGS), are among the primary factors propelling the market growth.

Access the full market insights report Request Sample

Companion diagnostics refer to medical tests that aid physicians in identifying the most suitable treatment strategy. They are crafted to detect specific biomarkers present in a patient's tissue or blood sample, indicating whether the patient is likely to respond positively to a particular drug or therapeutic approach. Additionally, they delve into the intricate biological profile and mechanism of action (MOA) of patients, assisting healthcare professionals in comprehending potential medication side effects. The widespread application of companion diagnostics is evident in personalized medicine, where it takes into account the distinct characteristics of each patient, such as their genetic composition, to determine the optimal treatment course. Beyond this, there is a growing use of companion diagnostics for examining specific genetic mutations in cancer patients or identifying biomarkers in those with hepatitis C.

JAPAN COMPANION DIAGNOSTICS MARKET TRENDS:

The Japan companion diagnostics market is experiencing significant growth, primarily propelled by the increasing incidence of diverse cancer types, which is fostering the demand for more precise and targeted cancer treatments. Additionally, the escalating demand for personalized medicines, tailored to the unique characteristics of each patient, further contributes to the optimistic market outlook. Simultaneously, the widespread adoption of targeted drugs and therapies addressing various infectious, cardiovascular, neurological, and inflammatory conditions serves as another substantial growth driver. The regulatory landscape for companion diagnostics in Japan is favorable, with an increasing number of tests receiving approvals. This, coupled with the expanding number of global clinical trials, strengthens the market growth. Ongoing advancements in diagnostic technologies, such as the emergence of next-generation sequencing (NGS) and liquid biopsy, are pivotal, enabling the identification of previously challenging-to-detect biomarkers. The development of innovative genomic technologies plays a key role, facilitating the identification of genetic mutations and biomarkers crucial for guiding treatment decisions, thereby fueling market growth. Additionally, factors like the growing use of biomarkers in drug development, substantial investments in precision medicine, and heightened consumer awareness regarding the benefits of companion diagnostics are projected to present lucrative growth opportunities for the regional market over the forecasted period.

JAPAN COMPANION DIAGNOSTICS MARKET SEGMENTATION:

Product & Service Insights:

To get detailed segment analysis of this market Request Sample
Assays, Kits and Reagents
Software and Services
Assays, Kits and Reagents
Software and Services

Technology Insights:

Immunohistochemistry (IHC)
Polymerase Chain Reaction (PCR)
In-situ Hybridization (ISH)
Real-time PCR (RT-PCR)
Gene Sequencing
Others
Immunohistochemistry (IHC)
Polymerase Chain Reaction (PCR)
In-situ Hybridization (ISH)
Real-time PCR (RT-PCR)
Gene Sequencing
Others

Indication Insights:

Cancer Lung Cancer Breast Cancer Colorectal Cancer Gastric Cancer Melanoma Others
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Melanoma
Others
Neurological Diseases
Infectious Diseases
Cardiovascular Diseases
Others
Cancer Lung Cancer Breast Cancer Colorectal Cancer Gastric Cancer Melanoma Others
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Melanoma
Others
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Melanoma
Others
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Melanoma
Others
Neurological Diseases
Infectious Diseases
Cardiovascular Diseases
Others

End User Insights:

Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
Contract Research Organizations
Others
Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
Contract Research Organizations
Others

Regional Insights:

To get detailed regional analysis of this market Request Sample
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT
How has the Japan companion diagnostics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan companion diagnostics market?
What is the breakup of the Japan companion diagnostics market on the basis of product & service?
What is the breakup of the Japan companion diagnostics market on the basis of technology?
What is the breakup of the Japan companion diagnostics market on the basis of indication?
What is the breakup of the Japan companion diagnostics market on the basis of end user?
What are the various stages in the value chain of the Japan companion diagnostics market?
What are the key driving factors and challenges in the Japan companion diagnostics?
What is the structure of the Japan companion diagnostics market and who are the key players?
What is the degree of competition in the Japan companion diagnostics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Companion Diagnostics Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Companion Diagnostics Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Companion Diagnostics Market - Breakup by Product & Service

6.1 Assays, Kits and Reagents
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Software and Services
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)

7 Japan Companion Diagnostics Market - Breakup by Technology

7.1 Immunohistochemistry (IHC)
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Polymerase Chain Reaction (PCR)
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 In-situ Hybridization (ISH)
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)
7.4 Real-time PCR (RT-PCR)
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2020-2025)
- 7.4.3 Market Forecast (2026-2034)
7.5 Gene Sequencing
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2020-2025)
- 7.5.3 Market Forecast (2026-2034)
7.6 Others
- 7.6.1 Historical and Current Market Trends (2020-2025)
- 7.6.2 Market Forecast (2026-2034)

8 Japan Companion Diagnostics Market - Breakup by Indication

8.1 Cancer
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Segmentation
  - 8.1.3.1 Lung Cancer
  - 8.1.3.2 Breast Cancer
  - 8.1.3.3 Colorectal Cancer
  - 8.1.3.4 Gastric Cancer
  - 8.1.3.5 Melanoma
  - 8.1.3.6 Others
- 8.1.4 Market Forecast (2026-2034)
8.2 Neurological Diseases
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Forecast (2026-2034)
8.3 Infectious Diseases
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Forecast (2026-2034)
8.4 Cardiovascular Diseases
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2020-2025)
- 8.4.3 Market Forecast (2026-2034)
8.5 Others
- 8.5.1 Historical and Current Market Trends (2020-2025)
- 8.5.2 Market Forecast (2026-2034)

9 Japan Companion Diagnostics Market - Breakup by End User

9.1 Pharmaceutical & Biopharmaceutical Companies
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2020-2025)
- 9.1.3 Market Forecast (2026-2034)
9.2 Reference Laboratories
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2020-2025)
- 9.2.3 Market Forecast (2026-2034)
9.3 Contract Research Organizations
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2020-2025)
- 9.3.3 Market Forecast (2026-2034)
9.4 Others
- 9.4.1 Historical and Current Market Trends (2020-2025)
- 9.4.2 Market Forecast (2026-2034)

10 Japan Companion Diagnostics Market - Breakup by Region

10.1 Kanto Region
- 10.1.1 Overview
- 10.1.2 Historical and Current Market Trends (2020-2025)
- 10.1.3 Market Breakup by Product & Service
- 10.1.4 Market Breakup by Technology
- 10.1.5 Market Breakup by Indication
- 10.1.6 Market Breakup by End User
- 10.1.7 Key Players
- 10.1.8 Market Forecast (2026-2034)
10.2 Kansai/Kinki Region
- 10.2.1 Overview
- 10.2.2 Historical and Current Market Trends (2020-2025)
- 10.2.3 Market Breakup by Product & Service
- 10.2.4 Market Breakup by Technology
- 10.2.5 Market Breakup by Indication
- 10.2.6 Market Breakup by End User
- 10.2.7 Key Players
- 10.2.8 Market Forecast (2026-2034)
10.3 Central/ Chubu Region
- 10.3.1 Overview
- 10.3.2 Historical and Current Market Trends (2020-2025)
- 10.3.3 Market Breakup by Product & Service
- 10.3.4 Market Breakup by Technology
- 10.3.5 Market Breakup by Indication
- 10.3.6 Market Breakup by End User
- 10.3.7 Key Players
- 10.3.8 Market Forecast (2026-2034)
10.4 Kyushu-Okinawa Region
- 10.4.1 Overview
- 10.4.2 Historical and Current Market Trends (2020-2025)
- 10.4.3 Market Breakup by Product & Service
- 10.4.4 Market Breakup by Technology
- 10.4.5 Market Breakup by Indication
- 10.4.6 Market Breakup by End User
- 10.4.7 Key Players
- 10.4.8 Market Forecast (2026-2034)
10.5 Tohoku Region
- 10.5.1 Overview
- 10.5.2 Historical and Current Market Trends (2020-2025)
- 10.5.3 Market Breakup by Product & Service
- 10.5.4 Market Breakup by Technology
- 10.5.5 Market Breakup by Indication
- 10.5.6 Market Breakup by End User
- 10.5.7 Key Players
- 10.5.8 Market Forecast (2026-2034)
10.6 Chugoku Region
- 10.6.1 Overview
- 10.6.2 Historical and Current Market Trends (2020-2025)
- 10.6.3 Market Breakup by Product & Service
- 10.6.4 Market Breakup by Technology
- 10.6.5 Market Breakup by Indication
- 10.6.6 Market Breakup by End User
- 10.6.7 Key Players
- 10.6.8 Market Forecast (2026-2034)
10.7 Hokkaido Region
- 10.7.1 Overview
- 10.7.2 Historical and Current Market Trends (2020-2025)
- 10.7.3 Market Breakup by Product & Service
- 10.7.4 Market Breakup by Technology
- 10.7.5 Market Breakup by Indication
- 10.7.6 Market Breakup by End User
- 10.7.7 Key Players
- 10.7.8 Market Forecast (2026-2034)
10.8 Shikoku Region
- 10.8.1 Overview
- 10.8.2 Historical and Current Market Trends (2020-2025)
- 10.8.3 Market Breakup by Product & Service
- 10.8.4 Market Breakup by Technology
- 10.8.5 Market Breakup by Indication
- 10.8.6 Market Breakup by End User
- 10.8.7 Key Players
- 10.8.8 Market Forecast (2026-2034)

11 Japan Companion Diagnostics Market - Competitive Landscape

11.1 Overview
11.2 Market Structure
11.3 Market Player Positioning
11.4 Top Winning Strategies
11.5 Competitive Dashboard
11.6 Company Evaluation Quadrant

12 Profiles of Key Players

12.1 Company A
- 12.1.1 Business Overview
- 12.1.2 Product Portfolio
- 12.1.3 Business Strategies
- 12.1.4 SWOT Analysis
- 12.1.5 Major News and Events
12.2 Company B
- 12.2.1 Business Overview
- 12.2.2 Product Portfolio
- 12.2.3 Business Strategies
- 12.2.4 SWOT Analysis
- 12.2.5 Major News and Events
12.3 Company C
- 12.3.1 Business Overview
- 12.3.2 Product Portfolio
- 12.3.3 Business Strategies
- 12.3.4 SWOT Analysis
- 12.3.5 Major News and Events
12.4 Company D
- 12.4.1 Business Overview
- 12.4.2 Product Portfolio
- 12.4.3 Business Strategies
- 12.4.4 SWOT Analysis
- 12.4.5 Major News and Events
12.5 Company E
- 12.5.1 Business Overview
- 12.5.2 Product Portfolio
- 12.5.3 Business Strategies
- 12.5.4 SWOT Analysis
- 12.5.5 Major News and Events

13 Japan Companion Diagnostics Market - Industry Analysis

13.1 Drivers, Restraints, and Opportunities
- 13.1.1 Overview
- 13.1.2 Drivers
- 13.1.3 Restraints
- 13.1.4 Opportunities
13.2 Porters Five Forces Analysis
- 13.2.1 Overview
- 13.2.2 Bargaining Power of Buyers
- 13.2.3 Bargaining Power of Suppliers
- 13.2.4 Degree of Competition
- 13.2.5 Threat of New Entrants
- 13.2.6 Threat of Substitutes
13.3 Value Chain Analysis